Armata Pharmaceuticals, Inc. (ARMP)

Armata Pharmaceuticals' stock has shown a 177.29% increase in the past six months. The company announced positive Phase 1b/2a diSArm study results for AP-SA02, meeting all primary endpoints. Armata formally commissioned its state-of-the-art cGMP phage manufacturing facility in Los Angeles, California. The company announced its third-quarter financial results and provided a corporate update. Armata entered into a secured credit agreement with Innoviva Strategic Opportunities LLC for a $15.0 million loan. The FDA agreed that Phase 2a diSArm data support advancing AP-SA02 to a Phase 3 superiority study. Jones Trading initiated coverage on Armata Pharmaceuticals with a "Buy" rating and a price target of $15.00.

There is no specific information available to indicate demand seasonality for Armata Pharmaceuticals, Inc.'s products and services. Demand for its products, once approved, would likely be driven by medical need rather than seasonal fluctuations. The nature of antibiotic-resistant infections suggests a consistent, year-round demand for effective treatments.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. The company operates in the Healthcare sector, specifically in the Biotechnology and Medical Research industry, utilizing its proprietary bacteriophage-based technology. Its major product candidates include AP-SA02 for Staphylococcus aureus bacteremia, AP-PA02 for Pseudomonas aeruginosa infections, and AP-PA03 for pneumonia. Armata also has a research collaboration agreement with Merck Sharp & Dohme Corp. and is a subsidiary of Innoviva, Inc.

Armata Pharmaceuticals, Inc. is headquartered in Los Angeles, California, United States. The company's 56,000 square foot facility in Los Angeles is built for phage product development, encompassing capabilities from bench to clinic, including in-house cGMP drug manufacturing suites. While its focus is on global antibiotic-resistant infections, the primary operational and manufacturing footprint appears to be in the United States.

Armata Pharmaceuticals' brand reputation in the past year appears to be largely positive, driven by advancements in its clinical trials and manufacturing capabilities. The positive topline data from the Phase 1b/2a diSArm study for AP-SA02 has significantly bolstered its reputation. The commissioning of its state-of-the-art cGMP phage manufacturing facility in Los Angeles demonstrates the company's commitment to quality and scalability. The FDA's agreement to advance AP-SA02 to a Phase 3 study is a strong validation of Armata's therapeutic approach. New "Buy" ratings from research firms like Jones Trading contribute to a positive market perception. Continued support from the U.S. Department of Defense for its AP-SA02 program also reflects positively on the company.

Armata Pharmaceuticals, Inc. has a significant portion of its ownership held by institutional and individual investors. As of January 5, 2026, 36 institutional owners held a total of 912,864 shares, including Vanguard Group Inc., Geode Capital Management, Llc, and State Street Corp. Innoviva Inc. is the largest individual shareholder, owning 25.08 million shares, representing 69.03% of the company. Insiders collectively own a substantial portion, around 69.48% of the company.